Introduction
Ketamine pharmacology encompasses the study of how the drug is absorbed, distributed throughout the body, metabolized, and eliminated. Understanding these pharmacokinetic properties is essential for clinicians who prescribe ketamine and for patients who want to understand why different routes of administration produce different effects, why dosing protocols vary, and how the drug interacts with other medications.
Ketamine is chemically classified as an arylcyclohexylamine, with the molecular formula C13H16ClNO and a molecular weight of 237.7 g/mol. It is a chiral molecule, meaning it exists in two mirror-image forms (enantiomers) with distinct pharmacological properties.
Enantiomers: S-Ketamine and R-Ketamine
Chirality and Clinical Significance
Ketamine contains a single chiral center at the C-2 carbon of its cyclohexanone ring, giving rise to two enantiomers: S(+)-ketamine (esketamine) and R(-)-ketamine (arketamine). Standard pharmaceutical ketamine is a racemic mixture, meaning it contains equal proportions of both enantiomers.
S-ketamine (esketamine) has approximately three to four times greater affinity for the NMDA receptor compared to R-ketamine. It is the more potent anesthetic and analgesic enantiomer and produces more pronounced psychotomimetic and dissociative effects. Esketamine is marketed as Spravato (nasal spray) for treatment-resistant depression.
R-ketamine (arketamine) has lower NMDA receptor affinity but has shown promising antidepressant effects in preclinical studies, potentially with fewer dissociative side effects. It may exert its effects through AMPA receptor-mediated mechanisms and BDNF signaling rather than through potent NMDA blockade. Several clinical trials of arketamine are currently underway.
Clinical Implications of Enantiomer Differences
The distinction between enantiomers has significant clinical implications. S-ketamine is a more potent anesthetic, so it can be used at lower doses for anesthesia. However, its stronger psychotomimetic effects may be either therapeutic (some clinicians believe dissociation correlates with antidepressant response) or undesirable (patients may find the experience distressing).
Absorption and Bioavailability
Routes of Administration
The bioavailability of ketamine — the fraction of the administered dose that reaches systemic circulation — varies dramatically by route of administration. This variation is one of the most clinically significant aspects of ketamine pharmacology.
Intravenous (IV): Bioavailability is 100% by definition. The standard antidepressant dose is 0.5 mg/kg infused over 40 minutes. Peak plasma levels are reached at the end of the infusion. This is the most studied route for psychiatric applications.
Intramuscular (IM): Bioavailability is approximately 93%. Onset is rapid, typically 3-5 minutes, with peak plasma levels at approximately 20 minutes. IM injection avoids hepatic first-pass metabolism, accounting for its high bioavailability.
Intranasal: Bioavailability ranges from 25% to 50%, with significant variability based on technique, nasal mucosa condition, and formulation. Spravato (esketamine) reports bioavailability of approximately 48%. Onset occurs within 5-10 minutes.
Sublingual/Buccal: Bioavailability ranges from 24% to 30%. Absorption occurs through the oral mucosa, partially bypassing hepatic first-pass metabolism. Onset is typically 15-30 minutes. Swallowed portions undergo significant first-pass metabolism, reducing effective bioavailability.
Oral: Bioavailability is approximately 16-24%. Extensive hepatic first-pass metabolism significantly reduces the amount of unchanged ketamine reaching systemic circulation. However, this route produces high levels of the active metabolite norketamine, which may have its own therapeutic properties.
Rectal: Bioavailability is approximately 25-30%. This route is occasionally used in pediatric anesthesia but is rarely employed for psychiatric applications.
Distribution
Plasma Protein Binding
Ketamine exhibits moderate plasma protein binding of approximately 10-30%, primarily to albumin and alpha-1 acid glycoprotein. This relatively low protein binding means that a large fraction of circulating ketamine is in the free (unbound) form and available to cross the blood-brain barrier.
Volume of Distribution
Ketamine has a large volume of distribution (approximately 3-5 L/kg), indicating extensive distribution into tissues. It is highly lipophilic, which enables rapid penetration across the blood-brain barrier and accounts for its fast onset of central nervous system effects.
Brain Penetration
Ketamine crosses the blood-brain barrier rapidly due to its lipophilicity and relatively small molecular size. Brain concentrations peak within minutes of IV administration. The drug distributes preferentially to highly perfused tissues including the brain, heart, and lungs before redistributing to muscle and fat.
The redistribution from brain to peripheral tissues is the primary factor in the termination of ketamine's acute clinical effects, rather than metabolism. This redistribution phase accounts for the relatively brief duration of dissociative effects (15-45 minutes after a standard infusion) despite the longer elimination half-life.
Metabolism
Hepatic Biotransformation
Ketamine is extensively metabolized in the liver through the cytochrome P450 (CYP) enzyme system. The primary metabolic pathway is N-demethylation to norketamine (N-desmethylketamine), mediated principally by CYP2B6 and CYP3A4, with minor contributions from CYP2C9, CYP2C19, and CYP2D6.
Norketamine
Norketamine is the major active metabolite of ketamine. It retains approximately 20-30% of the anesthetic potency of the parent compound and has a longer elimination half-life. There is growing evidence that norketamine may contribute meaningfully to ketamine's antidepressant effects, particularly when ketamine is administered orally (which produces proportionally higher norketamine levels due to first-pass metabolism).
Further Metabolic Steps
Norketamine undergoes further metabolism to hydroxynorketamine (HNK) isomers, with (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine being the most abundant. These HNK metabolites have attracted significant scientific interest since a 2016 study by Zanos et al. published in Nature demonstrated that (2R,6R)-HNK had antidepressant-like effects in mice without NMDA receptor blocking activity or dissociative properties.
If confirmed in human studies, this finding could lead to the development of ketamine-derived antidepressants that lack the psychotomimetic and abuse-related effects of the parent compound.
The HNK metabolites are further conjugated (glucuronidation) and excreted. Dehydronorketamine (DHNK) is another metabolite formed by dehydrogenation of norketamine, though it appears to have minimal pharmacological activity.
Elimination
Half-Life
The elimination half-life of ketamine is approximately 2-3 hours in adults. Norketamine has a slightly longer half-life of approximately 4-6 hours. The HNK metabolites persist even longer, with half-lives extending beyond 12 hours.
It is important to distinguish the elimination half-life from the duration of clinical effects. The dissociative and psychoactive effects of ketamine typically resolve within 1-2 hours after an IV infusion, driven primarily by redistribution rather than elimination. The antidepressant effects, however, can persist for days to weeks — far outlasting the presence of the drug in the body — because they are mediated by structural synaptic changes rather than ongoing receptor occupancy.
Renal Excretion
Approximately 90% of a ketamine dose is ultimately excreted by the kidneys, primarily as hydroxylated and conjugated metabolites. Less than 4% is excreted as unchanged ketamine. The remaining fraction is eliminated through fecal excretion.
Factors Affecting Elimination
Several factors influence ketamine's elimination rate:
- Age — Elderly patients generally have slower metabolism and may require dose adjustments
- Hepatic function — Liver disease can significantly impair ketamine metabolism, as the drug is almost entirely hepatically cleared
- CYP enzyme polymorphisms — Genetic variations in CYP2B6 and CYP3A4 can affect metabolic rates, leading to interindividual variability in drug levels
- Concurrent medications — CYP3A4 inhibitors (such as ketoconazole, clarithromycin, and grapefruit juice) can slow ketamine metabolism, while CYP3A4 inducers (such as rifampin and carbamazepine) can accelerate it
Drug Interactions
Pharmacokinetic Interactions
Medications that inhibit or induce CYP2B6 and CYP3A4 can alter ketamine plasma levels. Clinically significant interactions include:
- CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) — May increase ketamine levels
- CYP3A4 inducers (rifampin, phenytoin, carbamazepine) — May decrease ketamine levels
- CYP2B6 inhibitors (ticlopidine, clopidogrel) — May increase ketamine levels
Pharmacodynamic Interactions
- Benzodiazepines — May attenuate ketamine's psychoactive effects and potentially reduce its antidepressant efficacy. Some studies have found lower antidepressant response rates in patients taking concurrent benzodiazepines.
- Lamotrigine — This glutamate release inhibitor has been studied as a pretreatment to reduce ketamine's psychotomimetic effects. Results have been mixed regarding its impact on antidepressant efficacy.
- Opioids — Ketamine has been used as an adjunct to opioid therapy for pain management, and the two drug classes may have synergistic analgesic effects.
- MAOIs — Theoretical concern for hypertensive crisis, though clinical data are limited. Most clinicians exercise caution with this combination.
Clinical Pharmacology Considerations
Repeated Dosing and Tolerance
With repeated administration, some degree of pharmacodynamic tolerance develops to ketamine's dissociative and psychotomimetic effects. Many patients report that dissociation becomes less intense with successive treatments. Whether tolerance also develops to the antidepressant effects is a critical clinical question that remains under investigation — see our dedicated article on ketamine tolerance and sensitization for a thorough review of the evidence.
Pharmacogenomics
Genetic variations in metabolic enzymes, NMDA receptor subunits, BDNF (notably the Val66Met polymorphism), and other targets may influence individual responses to ketamine. Pharmacogenomic testing is not yet standard practice in ketamine therapy but represents a promising avenue for personalized medicine approaches.
Note: This article is for educational purposes. Dosing and medication interactions should always be discussed with a qualified healthcare provider.
References
- StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, pharmacokinetics, and drug interactions
- Ketamine Pharmacology: An Update — NIH review of ketamine pharmacodynamics, metabolism, and molecular aspects
- MedlinePlus: Ketamine Injection — National Library of Medicine information on ketamine administration and safety
- MedlinePlus: Esketamine Nasal Spray — Drug information on the S-enantiomer esketamine (Spravato)
Share